The Journal of urology · 2025
Gemcitabine vs Bacillus Calmette-Guérin for Intravesical Therapy in Treatment-Naïve Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khene Zine-Eddine, Bhanvadia Raj, Attia Sarah, Ito Willian, Trevino Ivan, Woldu Solomon L, Margulis Vitaly, Lotan Yair
Аннотация
PURPOSE: Patients with intermediate-risk (IR) nonmuscle-invasive bladder cancer (NMIBC) are recommended to receive induction intravesical chemotherapy or immunotherapy. However, the comparison between gemcitabine and bacillus Calmette-Guérin (BCG) in treatment-naïve patients with low-grade IR-NMIBC remains underexplored. The aim of this study was to evaluate the efficacy of gemcitabine compared with BCG in a cohort of treatment-naïve patients with IR-NMIBC.
MATERIALS AND METHODS: A retrospective analysis was conducted on patients with low-grade IR-NMIBC, classified according to International Bladder Cancer Group criteria, with no history of induction intravesical treatment. Patients received either induction intravesical BCG or gemcitabine. Recurrence was defined as histologically confirmed cancer during follow-up, while progression included stage/grade progression. Kaplan-Meier estimates were used for survival analysis, and multivariable Cox analysis identified factors associated with recurrence and progression.
RESULTS: Of the 151 patients with IR-NMIBC, 78 received BCG and 73 received gemcitabine. Both groups completed the 6-week induction treatment at similar rates (100%), and maintenance therapy was administered to 47% of BCG-treated patients and 53% of gemcitabine-treated patients (P = .46). The median number of maintenance doses was 6 (IQR: 3-9) in the BCG group and 8 (IQR: 4-10) in the gemcitabine group (P = .83). Median follow-up was 54 months for patients receiving BCG and 36 months for patients receiving gemcitabine. After adjusting for age, International Bladder Cancer Group subgroups, year of treatment, single postoperative instillation, and maintenance therapy, gemcitabine was associated with a higher risk of recurrence compared with BCG (P = .02), while the risk of progression remained similar between the 2 groups (P = .87). Adverse events were observed in 62% of patients treated with BCG and 38% of patients treated with gemcitabine (P = .02).
CONCLUSIONS: Gemcitabine is associated with a higher risk of recurrence than BCG in treatment-naïve patients with IR-NMIBC. However, both treatments show comparable efficacy in preventing disease progression.
MATERIALS AND METHODS: A retrospective analysis was conducted on patients with low-grade IR-NMIBC, classified according to International Bladder Cancer Group criteria, with no history of induction intravesical treatment. Patients received either induction intravesical BCG or gemcitabine. Recurrence was defined as histologically confirmed cancer during follow-up, while progression included stage/grade progression. Kaplan-Meier estimates were used for survival analysis, and multivariable Cox analysis identified factors associated with recurrence and progression.
RESULTS: Of the 151 patients with IR-NMIBC, 78 received BCG and 73 received gemcitabine. Both groups completed the 6-week induction treatment at similar rates (100%), and maintenance therapy was administered to 47% of BCG-treated patients and 53% of gemcitabine-treated patients (P = .46). The median number of maintenance doses was 6 (IQR: 3-9) in the BCG group and 8 (IQR: 4-10) in the gemcitabine group (P = .83). Median follow-up was 54 months for patients receiving BCG and 36 months for patients receiving gemcitabine. After adjusting for age, International Bladder Cancer Group subgroups, year of treatment, single postoperative instillation, and maintenance therapy, gemcitabine was associated with a higher risk of recurrence compared with BCG (P = .02), while the risk of progression remained similar between the 2 groups (P = .87). Adverse events were observed in 62% of patients treated with BCG and 38% of patients treated with gemcitabine (P = .02).
CONCLUSIONS: Gemcitabine is associated with a higher risk of recurrence than BCG in treatment-naïve patients with IR-NMIBC. However, both treatments show comparable efficacy in preventing disease progression.
Предметные рубрики MeSH
HumansGemcitabineUrinary Bladder NeoplasmsBCG VaccineDeoxycytidineRetrospective StudiesFemaleAdministration, IntravesicalMaleAgedMiddle AgedNeoplasm InvasivenessAdjuvants, ImmunologicNeoplasm GradingNeoplasm Recurrence, LocalDisease ProgressionAged, 80 and overTreatment OutcomeAntimetabolites, Antineoplastic